EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrative Bulk and Single-Cell Transcriptomics for Primitive Cell State-Informed Drug Repurposing in Acute Myeloid Leukemia

Xin Sun, Hongyi Li, Yujie Tang, Zhifan Huang, Chuandong Hou, Xinwei Sun, Pengcheng Liu, Haojun Zhang, Wenqian Zhou, Junyuan Chen, Jinfeng Li, Liangliang Wu und 1 weitere

Pharmaceuticals · 15.11.2026 · 19 (11) · 1814

DOI: 10.3390/ph19111814 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 15.11.2026. Verfasst von Xin Sun und 12 weiteren Autor:innen. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Acute myeloid leukemia (AML) exhibits marked cell-state heterogeneity, complicating the identification of candidate therapeutic vulnerabilities. We aimed to identify molecular features associated with primitive AML states and prioritize drugs for repurposing through integrative transcriptomic analyses.

Methods

Bulk CD34+ transcriptomes from 46 AML and 31 healthy samples and single-cell profiles from 16 AML and five healthy samples were analyzed using differential expression and coexpression network approaches. Putative regulators were inferred from chromatin-binding evidence and transcription factor activity. Drug prioritization combined expression-signature reversal and drug–gene associations. Tamoxifen (TAM) was evaluated in MV4-11, THP-1, MOLM-13, and SKM-1 cells using transcriptional and functional assays.

Results

GNL3L was the sole gene shared by four candidate gene sets; 17 putative regulators were identified. Four screening resources yielded eight overlapping drug candidates, and TAM was prioritized. TAM reduced viability and DNA synthesis and increased apoptosis in MV4-11, THP-1, MOLM-13, and SKM-1 cells. The G0/G1 fraction increased significantly in three lines, and mitochondrial membrane potential decreased in all four. E2F targets, G2/M checkpoint, and MYC targets showed predominantly negative enrichment, while the hematopoietic stem cell-like (HSC-like) marker signature showed inverse enrichment in seven of eight treatment comparisons. GNL3L protein decreased significantly in three cell lines, whereas p53 responses varied.

Conclusions

GNL3L emerged as a candidate associated with primitive AML states, and TAM warrants further investigation for drug repurposing. Regulatory causality, selectivity for primitive AML populations, and efficacy in primary AML samples and in vivo models remain unconfirmed.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Sun, X., Li, H., Tang, Y., Huang, Z., Hou, C., Sun, X., Liu, P., Zhang, H., Zhou, W., Chen, J., Li, J., Wu, L., & Lu, X. (2026). Integrative Bulk and Single-Cell Transcriptomics for Primitive Cell State-Informed Drug Repurposing in Acute Myeloid Leukemia. Pharmaceuticals, 19(11), 1814. https://doi.org/10.3390/ph19111814

Vancouver

Sun X, Li H, Tang Y, Huang Z, Hou C, Sun X, et al. Integrative Bulk and Single-Cell Transcriptomics for Primitive Cell State-Informed Drug Repurposing in Acute Myeloid Leukemia. Pharmaceuticals. 2026;19(11):1814. doi:10.3390/ph19111814

BibTeX
@article{Sun2026,
  author = {Sun, Xin and Li, Hongyi and Tang, Yujie and Huang, Zhifan and Hou, Chuandong and Sun, Xinwei and Liu, Pengcheng and Zhang, Haojun and Zhou, Wenqian and Chen, Junyuan and Li, Jinfeng and Wu, Liangliang and Lu, Xuechun},
  title = {Integrative Bulk and Single-Cell Transcriptomics for Primitive Cell State-Informed Drug Repurposing in Acute Myeloid Leukemia},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1814},
  doi = {10.3390/ph19111814}
}
Kostenlos starten →